8-K: Liminatus Pharma Regains Nasdaq Compliance After Timely 10-Q Filing

Liminatus Pharma, a pre-clinical stage biopharmaceutical company, announced it has regained compliance with Nasdaq listing requirements following the timely filing of its Quarterly Report on Form 10-Q.

Summary

• Liminatus Pharma, Inc. received a notice from the Nasdaq Listing Qualifications Department on May 29, 2025, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• The Company subsequently filed the Form 10-Q with the U.S. Securities and Exchange Commission on June 2, 2025.
• On June 3, 2025, Liminatus Pharma received a letter from Nasdaq stating that it had regained compliance with the Listing Rule, and the matter is now closed.
• A press release announcing the receipt of the non-compliance notice was issued by the Company on June 4, 2025, as required by Nasdaq Listing Rule 5810(b).

Sentiment

Score: 7

Explanation: While there was an initial negative event (non-compliance notice), the swift and successful resolution by filing the required document and regaining compliance is a strong positive, mitigating the initial concern.

Positives

• Liminatus Pharma successfully filed its Quarterly Report on Form 10-Q, addressing the previous delay.
• The Company promptly regained compliance with Nasdaq Listing Rule 5250(c)(1), resolving the non-compliance issue.
• The matter with Nasdaq regarding the filing delay is now officially closed, removing the immediate threat of delisting.

Negatives

• Liminatus Pharma initially failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• The Company received a formal notice of non-compliance from Nasdaq due to the filing delay, indicating a breach of listing rules.

Risks

• The Company faced a risk of delisting from The Nasdaq Stock Market LLC due to non-compliance with Nasdaq Listing Rule 5250(c)(1) for delayed filing, though this risk has now been resolved.

Future Outlook

Liminatus Pharma's vision is to develop a broad array of transformative therapies for cancer patients, aiming to become a leading global biopharmaceutical company. Their current candidate, IBA101, a humanized anti-CD47 monoclonal antibody, is expected to have its initial indication for patients with advanced solid cancers, including non-small cell lung cancer.

Management Comments

• Chris Kim, Chief Executive Officer, is listed as the contact for more information.

Industry Context

Liminatus Pharma is a pre-clinical stage biopharmaceutical company focused on developing novel, immune-modulating cancer therapies. Their lead candidate, IBA101, targets CD47, a common checkpoint inhibitor target in oncology, indicating their participation in the competitive and rapidly evolving field of cancer immunotherapy.

Stakeholder Impact

• Shareholders: The resolution of the non-compliance issue removes the immediate threat of delisting, which would have negatively impacted shareholder value and liquidity.

Key Dates

Keywords

Liminatus Pharma, Nasdaq, SEC filing, Form 10-Q, compliance, delisting, biopharmaceutical, cancer therapies, IBA101, CD47 checkpoint inhibitors